News

Data found that mavacamten significantly reduces cardiac obstruction and improves clinical markers in adolescents with symptomatic obstructive hypertrophic cardiomyopathy.

A study found that children who experience the death of a parent from overdose, homicide, or suicide face increased mortality rates.

The FDA has updated its approval for 1-mg epinephrine nasal spray, removing the age limit to allow all patients weighing at least 33 lb to access the treatment.

A review of 6 drugs approved by the FDA in Q1 2026, with links to coverage from Contemporary Pediatrics.

Rachel Rosales, MPH, explores how mandatory reporting and integrated care models can address the structural barriers preventing consistent behavioral health screenings.

Pediatric nutrition counseling transforms conversations by focusing on inclusion, behaviors, and barriers, fostering meaningful change for families.

Pediatric visits make nutrition doable: quick questions, budget-smart swaps, myth-busting advice, and family meals that boost kids’ growth.

A review of 4 drugs to be discussed by the US FDA during Q2 2026, with links to coverage from MJH Life Sciences publications.

As we step into Q2 2026, take a look back at our top video interviews and packages of Q1.

Get caught up with Contemporary Pediatrics. This list helps you navigate our top stories from the week, all in one place.

A 7460% increase in pediatric inhalation exposures since 2016 highlights the need for child-resistant designs and updated parental guidance.

The FDA has updated its approval for 1-mg epinephrine nasal spray, removing the age limit to allow all patients weighing at least 33 lb to access the treatment.

Linda Stein Gold, MD, discusses the promising safety and efficacy of tapinarof cream, 1%, as a nonsteroidal treatment for pediatric patients with atopic dermatitis.

Jennifer Hoffmann, MD, MS, discusses the high rates of overtriage in children with behavioral health symptoms and the need for more objective triage tools.

Researchers found no significant differences in laboratory abnormalities among children with PANS, OCD, and tic disorders.

A recent study found no significant correlation between childhood atopic dermatitis and an increase in cardiovascular risk markers.

This new once-weekly intravenous therapy aims to treat the neurologic manifestations of Hunter syndrome in young children.

Margeaux Naughton, MD, discusses the Pediatric Psychiatry Colocalized Consult Clinic model, a strategic approach to improve mental health access and provider training.

Ashley Shoemaker, MD, MSci, discusses the evolving clinical pathways for managing rare genetic and acquired hypothalamic obesity in pediatric patients.

The FDA approval of setmelanotide for patients 4 years and older offers a targeted therapy to address the underlying biology of acquired hypothalamic obesity.

A study found that the UTICalc tool effectively and accurately detects urinary tract infections in febrile children.

Clinical and family goals should guide the selection between high-dose CIMT and bimanual therapy.

A poll found that while many parents worry about youth driving accidents, most fail to recognize unsafe habits in their own children behind the wheel.

Shara Bialo, MD, explains why immunologic screening for islet autoantibodies is essential to identifying type 1 diabetes in its presymptomatic stages.

Palynziq provides a significant new genotype-independent therapy for patients 12 years and older to help manage and reduce blood phenylalanine levels.

Chad Wells, PhD, shares evidence-based strategies to improve MenACWY 2-dose series completion and address racial and socioeconomic disparities in vaccination.

Kathleen Adelgais, MD, MPH, highlights the critical role of family-centered protocols in overcoming readiness barriers and improving emergency outcomes for children.

A first-of-its-kind approval for hypothalamic obesity offers earlier, targeted treatment in children.